This article was downloaded by: On: 23 January 2011 Access details: Access Details: Free Access Publisher Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Journal of Carbohydrate Chemistry

Publication details, including instructions for authors and subscription information: http://www.informaworld.com/smpp/title~content=t713617200

Synthetic Studies Towards the O-Specific Polysaccharide of Shigella Sonnei

Adél Medgyes; István Bajza; Erzsébet Farkas; Vince Pozsgay; András Lipták

To cite this Article Medgyes, Adél, Bajza, István, Farkas, Erzsébet, Pozsgay, Vince and Lipták, András(2000) 'Synthetic Studies Towards the *O*-Specific Polysaccharide of *Shigella Sonnei*', Journal of Carbohydrate Chemistry, 19: 3, 285 – 310 **To link to this Article: DOI:** 10.1080/07328300008544079

URL: http://dx.doi.org/10.1080/07328300008544079

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

SYNTHETIC STUDIES TOWARDS THE O-SPECIFIC POLYSACCHARIDE OF

SHIGELLA SONNEI[†]

Adél Medgyes,¹ István Bajza,² Erzsébet Farkas,¹ Vince Pozsgay,³ and András Lipták^{1,2,*}

¹Institute of Biochemistry, Lajos Kossuth University, Debrecen, ²Research Group for Carbohydrates of the Hungarian Academy of Sciences, ³Laboratory of Developmental and Molecular Immunity, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, U.S.A.

Received August 18, 1999 - Final Form January 3, 2000

ABSTRACT

Synthetic routes are described to zwitter-ionic disaccharides that are diastereoisomerically related to frame-shifted repeating units of the title polysaccharide that contains 2-acetamido-4-amino-2,4,6-trideoxy-D-galactose and 2-acetamido-2-deoxy-L-altruronic acid. The intermediates corresponding to the trideoxygalactose residue feature acylamino functions at C-2 and an azido group at C-4. Best results were obtained with *N*-phthaloyl- and *N*-trichloroacetyl-protected derivatives. The intermediates corresponding to the uronic acid residue were either a D-altruronic acid-derived acceptor or a D-altrose-derived donor in which C-6 was oxidized after disaccharide formation.

INTRODUCTION

Shigellae are among the most common causative organisms of dysentery, an acute inflammatory disease of the lower intestines. Because of their resistance to most available

[†] Dedicated to Professor Pierre Sinaÿ on his first birthday in the third millenium.

antibiotics, prevention might be an alternative to treatment to combat this disease. An essential virulence factor of *Shigella* strains is the *O*-specific polysaccharide (O-SP) component of their lipopolysaccharides.¹ Robbins and co-workers suggested that a critical level of serum IgG antibodies to the O-SP of enteric bacteria may confer immunity to infection by the homologous organism.²⁻⁴ It appeared to us that such antibodies may be induced by protein conjugates of oligosaccharide fragments of the O-SPs. Our long-term goal is to prepare protein conjugates of synthetic oligosaccharide fragments of the O-SP of *Sh. sonnei* for the evaluation of their immunogenicity.

The O-SP of *Sh. sonnei* is built up of a disaccharide repeating unit (Figure 1) consisting of the rare monosaccharides 2-acetamido-4-amino-2,4,6-trideoxy-D-galactose (A) and 2-acetamido-2-deoxy-L-altruronic acid (B).⁵⁻⁷



Figure 1. The repeating unit of the polysaccharide

The starting material in our published approach to the L-AltNAcA moiety is Lglucose.⁸ The high price of this compound (\$ 30/g, Sigma) requires careful optimization of each step in the synthetic sequence. For the optimization experiments we used Dglucose to keep expenses at a minimum. In this report we describe synthetic studies towards the diastereomer analogues of the AB and BA disaccharides. In these analogues, AB(D) and B(D)A, the AltNAcA moiety has the unnatural D configuration. Because the success of the synthetic plan is crucially influenced by the *N*-protecting groups, several intermediates were designed and synthesized that only differ in the identity of the protecting groups at the C-2 amino groups.

RESULTS AND DISCUSSION

Glycosyl Donors Related to the Trideoxygalactose Moiety

Precursor to glycosyl donors 3-5 was the amino derivative 2 obtained upon treatment of thioglycoside⁸ 1 with ethylenediamine⁹ (Figure 2). Reaction of 2 with tetrachlorophthalic anhydride,¹⁰ trichloroacetyl chloride,¹¹ and 2,2,2-trichloroethylchloroformate,¹² respectively, afforded donors 3-5 in acceptable to good yields. Glycosyl trichloroacetimidate 7 was prepared from the hemiacetal 6 that was obtained by NBSmediated hydrolysis¹³ of thioglycoside 1. We note, that attempted conversion of thioglycosides 4 and 5 to the corresponding glycosyl trichloroacetimidates failed due to the formation of several by-products in attempted hydrolysis of thioglycoside linkage by NBS, NIS, NIS/TfOH, or MeOTf in wet dichloromethane.



Figure 2. Preparation of glycosyl donors

Glycosyl Acceptors Related to the Altruronic Acid Moiety

Common precursor in the syntheses of glycosyl acceptors corresponding to the uronic acid moiety was methyl glycoside 9 that was prepared in analogy to the corresponding L-enantiomer, by azide opening of the epoxide ring in compound $8.^8$ Treatment of 9 with LiAlH₄ afforded the amine 10 from which the N-phthalimido (11), N-

^{*}These intermediates are shown as if they assumed ${}^{4}C_{1}$ conformation. This is done for the purpose of convenience, only. The actual conformation of these intermediates has not been determined.





tetrachlorophthalimido (12), N-trichloroacetyl (13), and N-2,2,2-trichloroethoxycarbonyl derivatives (14) were prepared by conventional procedures. Acid-catalyzed hydrolytic removal of the benzylidene group from compounds 11-14 afforded the diols 15-18 that were regioselectively acylated at O-6 with a limiting amount of monochloroacetyl chloride to afford the partially protected derivatives 19-22.

In an alternative sequence, the benzylidene acetal 9 was routinely converted to the diol 23. Next, the primary carbon atom was selectively oxidized with the TEMPO/NaOCI reagent¹⁴ followed by treatment with MeI to afford the uronate 24. Catalytic reduction of the azido group provided the amine 25 which was conventionally *N*-acylated to afford glycosyl acceptors 26-29 (Figure 3).

Synthesis of AB(D) Disaccharide

Having readied glycosyl donors (1, 3-5, 7) and glycosyl acceptors (19-22, 26-29), we next investigated the effects of the *N*-protecting groups and the structure of the acceptor moieties on the outcome of glycosylation. The arbitrary criterium for pairing of the donor and the acceptor moieties was the identity of the *N*-protecting groups. In the glycosylation reactions (Table 1) the donors were used in a slight excess (1.2 equiv). Other conditions for the glycosylation reactions are to be found in the Experimental Part.

Item	Donor	Acceptor	Activator	Disaccharide	Yield (%)
1	1	19	NIS/TfOH	30	33
2	1	26	NIS/TfOH	No glycosylation	
3	3	20	NIS/TfOH	31	53
4	3	27	NIS/TfOH	No glycosylation	
5	4	21	NIS/TfOH	32	24
6	4	28	NIS/TfOH	33	62
7	5	22	NIS/TfOH	No glycosylation	
8	5	29	NIS/TfOH	No glycosylation	
9	7	19	TMSOTf	30	73

Table 1. Results of the glycosylation reactions

The results presented in Table 1 demonstrate that the nature of the *N*-protecting group had a significant effect on the yields of the glycosidation reactions. The best yield was obtained when the *N*-phthalyl-protected derivatives 7 and 19 were coupled under Schmidt-conditions¹⁵ (item 9). Combination of the *N*-TCA-protected partners 4 and 28 also gave the disaccharide in an acceptable yield (item 6). Couplings between the *N*-phthalyl-protected derivatives 1 and 19 or between the two *N*-TCP-protected partners 3 and 20 under NIS/TfOH activation¹⁶ proceeded in moderate yield. As expected, the reactivity of the uronic acid derivatives towards thioglycosides was poor (items 2, 4, 8). As an exception to this observation, glycosylation of the uronic acid derivative 28 with the donor 4 afforded a higher yield (item 6), than glycosylation of the chloroacetate 21 with the same donor (item 5). Surprisingly, the *N*-TeOC protection turned out to be unsuitable for the synthesis of the targeted disaccharide (items 7 and 8).



Figure 4.

Considering the glycosylation yields (Table 1) and the subsequent transformations that are necessary at the disaccharide level we have selected the route conducive to disaccharide 33 for further evaluation focusing on the efficiency of protecting group removal. This was performed in two steps. First, we subjected compound 33 to basic hydrolysis to cleave the ester moiety and to remove the *N*-TCA and *O*-acetyl groups. *N*-Acetylation of the intermediate so obtained afforded compound **34** in 62 % overall yield. We note, that attempted transformation of the TCA groups to acetyls under reductive conditions¹¹ failed to proceed in an acceptable yield. Next, the *O*-benzyl group was removed by hydrogenolysis and the azido group was simultaneously reduced to give the targeted disaccharide **35** in 78 % yield.

Synthesis of the B(D)A Disaccharide

Our initial approach to the BA disaccharide called for a N-trichloroacetylprotected donor corresponding to the ester 28. However, numerous attempts to convert 28 to either a glycosyl acetate by acetolysis or to a glycosyl chloride by treatment with dichloromethyl methýl ether¹⁷ proved to be abortive. In an alternative approach we decided to fashion the carboxyl after the assembly of an altrose-trideoxygalactose disaccharide. Thus, compound 23 was converted to ethylthio glycoside 37 through acetolysis (\rightarrow 36) followed by Lewis-acid catalyzed thioglycoside formation. Catalytic reduction of the N₃ function and consecutive amide formation yielded 38. Following NIS/TfOH promoted glycosylation of methyl 4-azido-2,4,6-trideoxy-2trichloroacetamido-B-D-galactopyranoside⁸ with 38 then gave disaccharide 39 in 84 % yield. Deacetylation of 39 provided the diol 40 which was oxidized at the primary carbon atom to afford 41 using phase-transfer-catalyzed TEMPO-mediated reaction.^{18,19} In this case we were able to isolate the free acid without converting it to the methyl ester. Deprotection of 41 was carried out as described for 33 to give the free disaccharide 43 in 40 % yield (Figure 5).

CONCLUSION

In summary, we have developed synthetic strategies to disaccharides 35 and 43 that are diastereomers of frame-shifted disaccharide repeating units of the O-specific polysaccharide of Shigella sonnei. We have used the D-enantiomer of the altruronic acid instead of the natural L-counterpart since it was readily synthesized from inexpensive Dglucose. Minding that there may be substantial differences in glycosylation of two enantiomers of an acceptor protected with a bulky N-phthalimido group,²⁰ we have also prepared derivatives having other N-protecting groups (trichloroacetamido, 2,2,2-



Figure 5.

trichloroethoxycarbonyl). The best results could be obtained in the condensation reactions of the *N*-phthalyl- (7 and 19) and *N*-trichloroacetyl-protected derivatives (4 and 28).

EXPERIMENTAL

General methods. Optical rotations were measured at rt with a Perkin-Elmer 241 automatic polarimeter in CHCl₃. Melting points were determined on a Kofler apparatus and are uncorrected. TLC was performed on Kieselgel 60 F_{254} (Merck) with detection by charring with 50 % aqueous sulfuric acid. Column chromatography was performed on Silica gel 60 (Merck 0.063-0.200 mm). The ¹H (200, 360 and 500 MHz) and ¹³C NMR (50.3, 90.54, 125.76 MHz) spectra were recorded with Bruker WP-200 SY, Bruker AM-360 and Bruker DRX-500 spectrometers in CDCl₃ solutions, except when stated otherwise. Internal references: TMS (0.000 ppm for ¹H), CDCl₃ (77.00 ppm for ¹³C). Elemental analyses were performed at the analytical laboratories in Debrecen. Abbreviations: Ac = acetyl, Bzl = benzyl, CA = chloroacetyl, Et = ethyl, Me = methyl, Ph

= phenyl, Phth = phthaloyl, TeOC = 2,2,2-trichloroethoxycarbonyl, TCA = trichloroacetyl, TCP = tetrachlorophthaloyl.

Ethyl 2-Amino-4-azido-2,4,6-trideoxy-1-thio-β-D-galactopyranoside (2). A solution of compound⁸ 1 (1.9 g, 4.7 mmol) and ethylenediamine (5 mL) in EtOH (20 mL) was stirred under reflux for 3 h. The solution was concentrated and the residue was purified by chromatography (CH₂Cl₂/MeOH, 9:1) to yield 2 (1.36 g, 98 %) as a colourless syrup: $[\alpha]_D$ -12.5° (*c* 0.9); ¹H NMR δ 4.15 (d, 1H, J_{1,2} = 10.0 Hz, H-1), 3.69 (dd, 1H, J_{3,4} = 3.5 Hz, J_{4,5} = 1.5 Hz, H-4), 3.68 (dq, 1H, J_{5,6} = 6.5 Hz, H-5), 3.62 (dd, 1H, J_{2,3} = 9.5 Hz, H-3), 2.89 (t, 1H, H-2), 2.72 (m, 2H, SCH₂CH₃), 1.29, (t, 3H, SCH₂CH₃), 2.32 (bs, 3H, NH₂, OH), 1.36 (d, 3H, J_{5,6} = 6.5 Hz, H-6); ¹³C NMR δ 87.4 (C-1), 75.6, 73.6 (C-4, C-5), 65.2 (C-3), 53.1 (C-2), 24.0 (SCH₂CH₃), 17.9 (C-6), 15.1 (SCH₂CH₃).

Anal. Calcd for $C_8H_{16}N_4O_2S$ (232.30): C, 41.36; H, 6.94. Found: C, 41.30; H, 6.91.

Ethyl 3-*O*-Acetyl-4-azido-2,4,6-trideoxy-2-tetrachlorophthalimido-1-thio-β-Dgalactopyranoside (3). To a solution of amine 2 (100 mg, 0.43 mmol) in dry CH₂Cl₂ was added tetrachlorophthalic anhydride (123 mg, 0.47 mmol) at 0 °C. After 15 min, the mixture was concentrated. Pyridine (5 mL) and Ac₂O (2 mL) were added and stirring was continued overnight. The solution was concentrated and the brownish syrup was purified by column chromatography (hexane/acetone, 8:2) to yield 3 (132 mg, 57 %) as a white powder: $[\alpha]_D$ -32.7° (*c* 0.84); ¹H NMR δ 5.73 (dd, 1H, J_{2,3} = 10.6 Hz, J_{3,4} = 3.7 Hz, H-3), 5.21 (d, 1H, J_{1,2} = 10.6 Hz, H-1), 4.57 (t, 1H, H-2), 3.92 (d, 1H, H-4), 3.83 (dd, 1H, J_{5,6} = 6.3 Hz, H-5), 2.61 (m, 2H, SCH₂CH₃), 1.14 (t, 3H, SCH₂CH₃), 1.95 (s, 3H, CH₃CO), 1.32 (d, 3H, H-6) (m, 2H, SCH₂CH₃), (t, 3H, SCH₂CH₃); ¹³C NMR δ 170.3 (CH₃CO), 163.5 and 162.7 (C=O of TCP), 140.8, 130.1 and 127.0 (TCP), 80.3 (C-1), 73.5, 71.3 (C-4, C-5), 63.6 (C-3), 50.8 (C-2), 23.9 (SCH₂CH₃), 20.6 (*C*H₃CO), 17.9 (C-6), 14.8 (SCH₂CH₃).

Anal. Calcd for C₁₈H₁₆Cl₄N₄O₅S (542.22): C, 39.87; H, 2.97. Found: C, 39.79; H, 2.90.

Ethyl 3-O-Acetyl-4-azido-2,4,6-trideoxy-1-thio-2-trichloroacetamido-β-Dgalactopyranoside (4). To a solution of amine 2 (100 mg, 0.43 mmol) in dry CH_2Cl_2 (10 mL) were added triethylamine (100 μL) and trichloroacetyl chloride (53 μL, 0.47 mmol) at 0 °C. Stirring was continued for 20 min, followed by addition of pyridine (5 mL) and Ac₂O (2 mL). After 2 h the mixture was concentrated. Column chromatographic purification of the residue (hexane/EtOAc, 8:2) yielded pure 4 (171 mg, 94 %) as a white foam: $[\alpha]_D$ -52.05° (*c* 0.43); ¹H NMR δ 6.64 (bd, 1H, J_{2,NH} = 9.5 Hz, NH), 5.37 (dd, 1H, J_{2,3} = 10.5 Hz, J_{3,4} = 3.5 Hz, H-3), 4.63 (d, 1H, J_{1,2} = 10.0 Hz, H-1), 4.24 (ddd, 1H, J_{2,NH} = 9.5 Hz, H-2), 3.85 (dd, 1H, J_{4,5} = 1.5 Hz, H-4), 3.79 (dq, 1H, J_{5,6} = 6.5 Hz, H-5), 2.74 (m, 2H, SCH₂CH₃), 2.13 (s, 3H, CH₃CO), 1.37 (d, 3H, J_{5,6} = 6.5 Hz, H-6), 1.26 (t, 3H, SCH₂CH₃); ¹³C NMR δ 161.8 (Cl₃CCO), 83.3 (C-1), 73.6, 73.0 (C-4, C-5), 63.6 (C-3), 51.5 (C-2), 23.9 (SCH₂CH₃), 20.5 (CH₃CO), 17.7 (C-6), 14.8 (SCH₂CH₃).

Anal. Calcd for $C_{12}H_{17}Cl_3N_4O_4S$ (419.71): C, 34.34; H, 4.08. Found: C, 34.40; H, 4.10.

Ethyl 3-*O*-Acetyl-4-azido-2,4,6-trideoxy-1-thio-2-(2,2,2-trichloroethoxy carbonylamino)-β-D-galactopyranoside (5). To a stirred solution of amine 2 (100 mg, 0.43 mmol) in dry CH₂Cl₂ (10 mL) were added triethylamine (100 µL) and 2,2,2-trichloroethyl chloroformate (65 µL, 0.47 mmol) at 0 °C. After 15 min, pyridine (5 mL) and Ac₂O (2 mL) were added and stirring was continued for an additional 2 h. The mixture was concentrated. The residue was purified by column chromatography (hexane/EtOAc, 8:2) to yield pure 5 (161 mg, 83 %) as a white powder: $[\alpha]_D$ -41.6° (*c* 0.33); ¹H NMR δ 5.25 (dd, 1H, J_{2,3} = 10.0 Hz, J_{3,4} = 3 Hz, H-3), 5.05 (bd, 1H, NH), 4.80 and 4.69 (bd, 2x1H, Cl₃CCH₂), 4.56 (d, 1H, J_{1,2} = 10.0 Hz, H-1), 3.97 (ddd, 1H, J_{2,NH} = 10.0 Hz, H-2), 3.83 (dd, 1H, J_{4,5} = 1.0 Hz, H-4), 3.75 (bd, 1H, J_{5,6} = 6.0 Hz, H-5), 2.73 (m, 2H, SCH₂CH₃), 2.12 (s, 3H, CH₃CO), 1.35 (d, 3H, J_{5,6} = 6 Hz, H-6), 1.26 (t, 3H, SCH₂CH₃); ¹³C NMR δ 170.5 (CH₃CO), 154.0 (Cl₃CCH₂OCO), 83.9 (C-1), 74.5 (Cl₃CCH₂), 73.4, 73.3 (C-4, C-5), 63.6 (C-3), 51.3 (C-2), 23.8 (SCH₂CH₃), 20.6 (CH₃CO), 17.7 (C-6), 14.7 (SCH₂CH₃).

Anal. Calcd for $C_{13}H_{19}Cl_{3}N_{4}O_{5}S$ (449.74): C, 34.72; H, 4.26. Found: C, 34.68; H, 4.19.

3-O-Acetyl-4-azido-2,4,6-trideoxy-2-phthalimido- β -D-galactopyranosyl trichloroacetimidate (7). To a chilled solution of 1 (260 mg, 0.64 mmol) in a 9:1 mixture of acetone/water (10 mL) *N*-bromosuccinimide (170 mg, 0.96 mmol) was added portionwise. After 20 min the reaction mixture was concentrated until turbidity and the residue diluted with EtOAc (100 mL). Extractive work-up followed by chromatography (CH₂Cl₂/EtOAc, 9:1) yielded pure 3-O-acetyl-4-azido-2,4,6-trideoxy-2-phthalimido-D-galactopyranose (6) (200 mg, 87 %) as a colourless syrup. $[\alpha]_D$ –6.1° (*c* 1.04). To a solution of 6 (136 mg, 0.36 mmol) in dry CH₂Cl₂ (5 mL) trichloroacetonitrile (400 µL) and K₂CO₃ (500 mg) were added. The suspension was stirred at rt for 3h. Inorganic salts were removed by filtration, the cake was washed with CH₂Cl₂ (2 x 10 mL) and the filtrate was concentrated to yield 7 (146 mg, 80 %) as a white foam which was used in glycosylation reactions without any purification.

Methyl 2-Amino-3-O-benzyl-4,6-O-benzylidene-2-deoxy- α -D-altropyranoside (10). To a stirred solution of 9 (4.0 g, 10 mmol) in dry tetrahydrofuran (60 mL), LiAlH₄ (800 mg, 20 mmol) was added and stirring was continued for 1.5 h. The excess of the hydride was decomposed by addition of EtOAc (200 mL) and water, then the solution was extracted with brine (2 x 100 mL) the organic layer was separated, dried, and concentrated to yield crude 10 (3.68 g, 98 %) which was used in the next steps without further purification.

Methyl 3-O-Benzyl-4,6-O-benzylidene-2-deoxy-2-phthalimido-α-D-altropyranoside (11). To an ice cold solution of crude 10 (370 mg, 0.99 mmol) and triethylamine (1.6 mL) in dry CH₂Cl₂ (10 mL), a solution of 2-methoxycarbonylbenzoyl chloride [prepared from 270 mg (1.1 mmol) of phthalic acid monomethyl ester and 3 mL of thionyl chloride] in dry CH₂Cl₂ (2 mL) was added dropwise. The mixture was stirred for 16 h at rt, then concentrated. Extractive work-up of the residue followed by column chromatography (hexane/EtOAc, 8:2 then 7:3) yielded pure 11 (430 mg, 85 %) as a white foam: $[\alpha]_D -4^\circ$ (*c* 0.99); ¹H NMR δ 7.80, 7.45 and 7.10 (3m, 14H, aromatic), 5.62 (s, 1H, PhC*H*), 4.98 (d, 1H, J_{1,2} = 3.0 Hz, H-1), 4.77 (t, 1H, J_{2,3} = 3.0 Hz, H-2), 4.47 (m, 2H, H-6, H-6'), 4.38 (dd, 1H, J_{3,4} = 3.0, J_{4,5} = 10.0 Hz, H-4), 3.99 (t, 1H, H-3), 3.39 (s, 3H, OC*H*₃); ¹³C NMR δ 167.5 (C=O), 101.9 (PhCH), 98.2 (C-1), 76.5, 73.7, 72.6 (PhCH₂), 69.8 (C-6), 59.2, 55.4, 54.6.

Anal. Calcd for C₂₉H₂₇NO₇ (501.54): C, 69.45; H, 5.43. Found: C, 69.41; H, 5.42.

Methyl 3-O-Benzyl-4,6-O-benzylidene-2-deoxy-2-tetrachlorophthalimido- α -D-altropyranoside (12). To a stirred solution of crude 10 (510 mg, 1.37 mmol) in CH₂Cl₂ (10 mL) was added tetrachlorophthalic anhydride (432 mg, 1.5 mmol). After 30 min diisopropylethylamine (1 mL) was added. The mixture was stirred under reflux for 4 h followed by concentration. Column chormatographic purification (hexane/EtOAc, 9:1) of the residual syrup afforded 12 (470 mg, 54 %): $[\alpha]_D$ -90° (c 0.88); ¹H NMR δ 7.3 (m, 10H, aromatic), 5.63 (s, 1H, PhC*H*), 4.98 (d, 1H, J_{1,2} = 4.5 Hz, H-1), 4.81, 4.65 (2d, 2H, PhC*H*₂), 4.69 (t, 1H, J_{2,3} = 4.5 Hz, H-2), 4.43 (m, 2H, H-5, H-6'), 4.29 (dd, 1H, J_{3,4} = 4.5, J_{4,5} = 10.0 Hz, H-4), 4.06 (t, 1H, H-3), 3.84 (t, 1H, J_{5,6} = J_{6,6'} = 12.0 Hz, H-6), 3.36 (s, 3H, OC*H*₃).

Anal. Calcd for $C_{29}H_{23}Cl_4NO_7$ (639.32): C, 54.48; H, 3.63. Found: C, 54.38; H, 3.63.

Methyl 3-*O*-Benzyl-4,6-*O*-benzylidene-2-deoxy-2-trichloroacetamido-α-Daltropyranoside (13). To a chilled solution of 10 (520 mg, 1.4 mmol) in dry CH₂Cl₂ (10 mL) containing triethylamine (500 µL, 3.8 mmol) was added trichloroacetyl chloride (166 µL, 1.54 mmol) and the stirring was continued for 1 h. The mixture was diluted with CH₂Cl₂ (200 mL). Extractive work-up followed by column chromatographic purification of the residue (hexane/EtOAc, 8:2) yielded pure 13 (550 mg, 76 %): $[\alpha]_D$ +48.2° (*c* 0.26); ¹H NMR δ 7.40 (m, 5H, aromatic), 7.25 (bd, 1H, J_{2,NH} = 8.5 Hz, NH), 5.58 (s, 1H, PhC*H*), 4.87 and 4.81 (2d, 2H, PhC*H*₂), 4.65 (s, 1H, H-1), 4.51 (m, 1H, J_{4,5} = 10.0 Hz, J_{5,6} = 5.0 Hz, J_{5,6} = 10.0 Hz, H-5), 4.42 (dd, 1H, J_{2,NH} = 8.5 Hz, J_{2,3} = 2.5 Hz, H-2), 4.34 (dd, 1H, H-5), 4.42 (dd, 1H, J_{2,NH} = 8.5 Hz, M-4), 3.45 (s, 3H, OCH₃); ¹³C NMR δ 161.2 (C=O), 102.4 (PhCH), 100.2 (C-1), 77.2, 73.2, 58.6 (C-3, C-4, C-5), 72.6 (PhCH₂), 69.1 (C-6), 55.9 (C-2), 52.5 (OCH₃).

Anal. Calcd for C₂₃H₂₄Cl₃NO₆ (516.81): C, 53.45; H, 4.68. Found: C, 53.40; H, 4.67.

Methyl 3-*O*-Benzyl-4,6-*O*-benzylidene-2-deoxy-2-(2,2,2-trichloroethoxycarbonylamino)-α-D-altropyranoside (14). To a stirred solution of amine 10 (400 mg, 1.08 mmol) in dry CH₂Cl₂ (10 mL) were added triethylamine (500 µL), and 2,2,2trichloroethyl chloroformate (164 µL, 1.2 mmol) at 0 °C and stirring was continued for 1 h. After work-up and purification 340 mg (58 %) of pure 14 was isolated: $[\alpha]_D$ +26.4° (*c* 0.3); ¹H NMR δ 7.35 (m, 10H, aromatic), 5.57 (s, 1H, PhC*H*), 5.22 (d, 1H, J_{2,NH} = 8.5 Hz, NH), 4.83 (d, 2H, Cl₃CC*H*₂), 4.76 and 4.68 (2d, 2H, PhC*H*₂), 4.63 (s, 1H, H-1), 4.47 (dt, 1H, $J_{4,5} = J_{5,6} = 10.0$ Hz, $J_{5,6} = 5.0$ Hz, H-5), 4.34 (dd, 1H, $J_{6,6} = 10.0$ Hz, H-6), 4.24 (dd, 1H, $J_{2,NH} = 8.5$ Hz, $J_{2,3} = 2.5$ Hz, H-2), 3.93 (t, 1H, $J_{3,4} = 3.0$ Hz, H-3), 3.75 (dd, 1H, H-4), 3.74 (t, 1H, H-6'), 3.43 (s, 3H, OCH₃); ¹³C NMR δ 153.5 (C=O), 102.4 (PhCH), 100.9 (C-1), 76.9, 73.9, 58.5 (C-3, C-4, C-5), 74.8 (CCl₃CH₂OCO), 72.4 (PhCH₂), 69.3 (C-6), 55.8 (C-2), 52.5 (OCH₃).

Anal. Calcd for C₂₄H₂₆Cl₃NO₇ (546.83): C, 52.72; H, 4.79. Found: C, 52.69; H, 4.77.

Methyl 3-O-Benzyl-2-deoxy-2-phthalimido- α -D-altropyranoside (15). To a solution of 11 (800 mg, 1.6 mmol) in CH₂Cl₂ (20 mL) were added trifluoroacetic acid (1 mL) and water (0.5 mL) at rt. After 30 min, the mixture was concentrated. Toluene (10 mL) was added to and evaporated from the residue twice. Column chromatography of the residual syrup (hexane/acetone, 6:4) yielded pure 15 (500 mg, 76 %) as a colourless oil: $[\alpha]_D$ –11° (*c* 1.05); ¹H NMR δ 7.75 (m, 4H, Phth), 7.02 (bs. 5H, aromatic), 4.18 (d, 1H, J_{1,2} = 6.0 Hz, H-1), 4.6 and 4.35 (2d, 2H, PhCH₂), 4.57 (dd, 1H, J_{2,3} = 10.5 Hz, H-2), 4.23 (bt, 1H, J_{3,4} = J_{4,5} = 4.4 Hz, H-4), 4.11 (m,1H, H-5), 3.89 (bs, 2H, H-6, H-6'), 3.38 (s, 3H, OCH₃), 3.05 and 2.73 (2bs, 2x1H, OH).

Anal. Calcd for C₂₂H₂₃NO₇ (413.43): C, 63.92; H, 5.61. Found: C, 63.89; H, 5.60.

Methyl 3-*O*-Benzyl-2-deoxy-2-tetrachlorophthalimido-α-D-altropyranoside (16). Prepared from 12 (450 mg, 0.7 mmol) as described above for the preparation of compound 15. Chromatographic purification (CH₂Cl₂/acetone, 8:2) resulted in pure 16 (300 mg, 77 %): ¹H NMR δ 7.25 (m, 5H, aromatic), 4.52 (d, 1H, $J_{1,2} = 5$ Hz, H-1), 4.61, 4.42 (2d, 2H, PhCH₂), 4.29 (t, 1H, $J_{2,3} = 4.5$ Hz, H-2), 4.13 (m, 3H, H-5, H-6, H-6), 4.02 (t, 1H, H-3), 3.33 (s, 3H, OCH₃). ¹³C NMR δ (DMSO-d₆) 163.0 (C=O), 97.1 (C-1), 77.5, 72.8, 63.9 (C-3, C-4, C-5), 70.2 (PhCH₂), 60.9 (C-6), 54.8 (C-2), 52.5 (OCH₃).

Anal. Calcd for C₂₂H₁₉Cl₄NO₇ (551.21): C, 47.94; H, 3.47. Found: C, 47.95; H, 3.46.

Methyl 3-O-Benzyl-2-deoxy-2-trichloroacetamido- α -D-altropyranoside (17). Prepared from 13 (980 mg, 1.9 mmol) as described above for the preparation of compound 15. Chromatographic purification (CH₂Cl₂/acetone, 8:2) yielded pure 17 (675 mg, 83 %): $[\alpha]_D$ +84.2° (c 0.98); ¹H NMR δ 7.35 (m, 5H, aromatic), 6.87 (bd, 1H, J_{2,NH} = 8.5 Hz, NH), 4.93 and 4.56 (d, 2H, PhCH₂), 4.69 (s, 1H, H-1), 4.47 (dd, 1H, $J_{2,3} = 3.0$ Hz, H-2), 3.98 (m, 1H, H-5), 3.87 (m, 3H, H-3, H-6, H-6'), 3.69 (bd, 1H, H-4), 3.44 (s, 3H, OCH₃), 2.52 (bs, 1H, OH), 1.9 (bs, 1H, OH); ¹³C NMR δ 99.4 (C-1), 74.6, 68.7, 64.4 (C-3, C-4, C-5), 71.8 (PhCH₂), 62.5 (C-6), 55.8 (C-2), 50.1 (OCH₃).

Anal. Calcd for C₁₆H₂₀Cl₃NO₆ (428.70): C, 44.83; H, 4.70. Found: C, 44.80; H, 4.71.

Methyl 3-*O*-Benzyl-2-deoxy-2-(2,2,2-trichloroethoxycarbonylamino)-α-Daltropyranoside (18). Prepared from 14 (320 mg, 0.59 mmol) as described above for the preparation of compound 15. Chromatographic purification (CH₂Cl₂/acetone, 8:2) afforded pure 18 (270 mg, 96 %): $[\alpha]_D$ +80.3° (*c* 0.93); ¹H NMR δ 7.35 (m, 5H, aromatic), 5.60 (d, 1H, J_{2,NH} = 8.5 Hz, NH), 4.91 and 4.51 (2d, 2H, PhCH₂), 4.77 and 4.71 (2d, 2x1H, Cl₃CCH₂), 4.65 (s, 1H, H-1), 4.31 (dd, 1H, J_{2,NH} = 8.5 Hz, J_{2,3} = 2.5 Hz, H-2), 3.85 (m, 5H, H-3, H-4, H-5, H-6, H-6'), 3.40 (s, 3H, OCH₃), 2.58 and 2.24 (d, and bs, 2x1H, 2 x OH); ¹³C NMR δ 153,9 (Cl₃CCH₂OCO), 100.2 (C-1), 75.5, 68.5, 64.0 (C-3, C-4, C-5), 74.7 (Cl₃CCH₂), 71.5 (PhCH₂), 62.5 (C-6), 55.6 (C-2), 49.9 (OCH₃).

Anal. Calcd for $C_{17}H_{22}Cl_3NO_7$ (458.72): C, 44.51; H, 4.83. Found: C, 44.52; H, 4.9.

Methyl 3-*O*-Benzyl-6-*O*-chloroacetyl-2-deoxy-2-phthalimido-α-D-altropyranoside (19). To a solution of 15 (3.44 g, 8.2 mmol) and triethylamine (2.7 mL) in dry CH₂Cl₂ (60 mL), was added chloroacetyl chloride (780 µL, 9.8 mmol) at -40 °C and the mixture was stirred at -40 °C for 30 min. The mixture was diluted with CH₂Cl₂ (200 mL) and after extractive work-up the crude syrup was chromatographed (hexane/EtOAc, 6:4) to yield pure 19 (3.60 g, 90 %): $[\alpha]_D$ –13° (*c* 0.99); ¹H NMR δ 7.80 (m, 4H, Phth), 7.10 (m. 5H, aromatic), 5.17 (d, 1H, J_{1,2} = 7.0 Hz, H-1), 4.45 (m, 4H, H-2, H-3, H-6, H-6'), 4.26 (dd, 1H, H-5), 4.15 (s, 2H, ClCH₂), 4.06 (t, 1H, J_{3,4} = J_{4,5} = 4.5 Hz, H-4), 3.34 (s, 3H, OCH₃), 2.87 (bs, 1H, OH).

Anal. Calcd for $C_{24}H_{24}CINO_8$ (489.91): C, 58.84; H, 4.94. Found: C, 58.83; H, 4.91.

Methyl 3-O-Benzyl-6-O-chloroacetyl-2-deoxy-2-tetrachlorophthalimido- α -Daltropyranoside (20). To a solution of 16 (300 mg, 0.54 mmol) in dry pyridine (10 mL) was added chloroacetyl chloride (51 μ L, 0.65 mmol) at -50 °C. After 1 h stirring the mixture was concentrated and the crude syrup was purified by chromatography (hexane/EtOAc, 7:3) to yield **20** (210 mg, 62 %): $[\alpha]_D$ -43.7° (*c* 0.35); ¹H NMR 7.10 (m. 5H, aromatic), 4.77 (d, 1H, $J_{1,2} = 6.0$ Hz, H-1), 4.35 (m, 4H, H-2, H-3, H-6, H-6'), 4.26 (dd, 1H, H-5), 4.15 (s, 2H, ClCH₂), 4.06 (t, 1H, $J_{3,4} = J_{4,5} = 4.5$ Hz, H-4), 3.34 (s, 3H, OCH₃), 2.87 (bs, 1H, OH). ¹³C NMR δ 167.1 (ClCH₂CO), 163.2 (C=O), 97.6 (C-1), 73.2, 72.9, 65.9 (C-3, C-4, C-5), 72.8 (PhCH₂), 65.5 (C-6), 55.7 (C-2), 52.4 (OCH₃), 40.7 (ClCH₂).

Anal. Calcd for $C_{24}H_{20}Cl_5NO_8$ (627.69): C, 45.92; H, 3.21. Found: C, 45.90; H, 3.20.

Methyl 3-*O*-Benzyl-6-*O*-chloroacetyl-2-deoxy-2-trichloroacetamido-α-Daltropyranoside (21). Prepared from 17 (600 mg, 1.4 mmol) as described above for the preparation of compound 19. Chromatographic purification (hexane/EtOAc, 7:3) resulted in pure 21 (460 mg, 65 %): $[\alpha]_D$ +78.1° (*c* 0.54); ¹H NMR δ 7.4 (m, 5H, aromatic), 6.77 (d, 1H, J_{2,NH} = 8.5 Hz, NH), 4.93, 4.56 (2d, 2H, PhCH₂), 4.69 (s, 1H, H-1), 4.55 (dd, 1H, J_{5,6} = 2.0 Hz, J_{6,6} = 12.0 Hz, H-6), 4.48 (dd, 1H, J_{2,3} = 3.0 Hz, H-2), 4.43 (dd, 1H, J_{5,6'} = 5.5 Hz, H-6'), 4.16 (m, 1H, J_{4,5} = 9.5 Hz, H-5), 4.09 (s, 2H, CICH₂), 3.88 (t, 1H, J_{3,4} = 3.0 Hz, H-3), 3.68 (bd, 1H, H-4), 3.43 (s, 3H, OCH₃), 2.53 (bs, 1H, OH); ¹³C NMR δ 161.5 (Cl₃CCO), 99.3 (C-1), 74.2, 66.9, 63.8 (C-3, C-4, C-5), 71.8 (PhCH₂), 64.9 (C-6), 55.9 (C-2), 49.9 (OCH₃), 40.7 (CICH₂).

Anal. Calcd for $C_{18}H_{21}Cl_4NO_7$ (505.18): C, 42.80; H, 4.19. Found: C, 42.79; H, 4.17.

Methyl 3-*O*-Benzyl-6-*O*-chloroacetyl-2-deoxy-2-(2,2,2-trichloroethoxycarbonylamino)-α-D-altropyranoside (22). Prepared from 18 (260 mg, 0.57 mmol) as described above for the preparation of compound 19. Purification (hexane/EtOAc, 8:2) resulted in 22 (190 mg, 63 %): $[\alpha]_D$ +69.5° (*c* 0.14); ¹H NMR δ 7.4 (m, 5H, aromatic), 5.24 (d, 1H, J_{2,NH} = 9.0 Hz, NH), 4.91, 4.52 (2d, 2H, PhCH₂), 4.75 (d, 2H, Cl₃CCH₂), 4.54 (dd, 1H, J_{6,6'} = 12.0 Hz, J_{5,6} = 2.0 Hz, H-6), 4.42 (dd, 1H, J_{5,6'} = 6.0 Hz, J-6'), 4.31 (dd, 1H, J_{2,3} = 2.5 Hz, H-2), 4.1 (ddd, 1H, J_{4,5} = 10.0 Hz, H-5), 4.1 (s, 2H, ClCH₂), 3.83 (bt, 1H, J_{3,4} = 3.0 Hz, H-3), 3.68 (bm, 1H, H-4), 3.41 (s, 3H, OCH₃), 2.53 (bd, 1H, OH); ¹³C NMR δ 167.1 (ClCH₂CO), 153.7 (Cl₃CCH₂OCO), 99.9 (C-1), 95.2 (Cl₃CCH₂), 75.0, 66.8, 63.7 (C-3, C-4, C-5), 74.7 (Cl₃C*C*H₂), 71.5 (Ph*C*H₂), 65.2 (C-6), 55.7 (C-2), 49.7 (O*C*H₃), 40.8 (Cl*C*H₂).

Anal. Calcd for C₁₉H₂₃Cl₄NO₈ (535.21): C, 42.64; H, 4.33. Found: C, 42.60; H, 4.32.

Methyl 2-Azido-3-*O*-benzyl-2-deoxy- α -D-altropyranoside (23). To a stirred solution of 9⁸ (4.0 g, 10.06 mmol) in CH₂Cl₂ (50 mL) were added trifluoroacetic acid (5 mL) and water (1 mL) at rt. After 30 min the reaction mixture was concentrated then co-concentrated with toluene (2 x 20 mL) and the crude syrup was purified by chromatography (CH₂Cl₂/acetone, 8:2) to yield pure 23 (3.01 g, 96 %): [α]_D +75.2° (*c* 0.58); ¹H NMR δ 7.10 (m, 5H, aromatic), 4.98 (d, 1H, J_{1,2} = 3.0 Hz, H-1), 4.77 (t, 1H, J_{2,3} = 3.0 Hz, H-2), 4.47 (m, 2H, H-6, H-6'), 4.38 (dd, 1H, J_{3,4} = 3.0 Hz, J_{4,5} = 10.0 Hz, H-4), 3.99 (t, 1H, H-3), 3.39 (s, 2H, OCH₃); ¹³C NMR δ 98.2 (C-1), 76.5, 73.7, 72.6 (PhCH₂), 69.8 (C-6), 59.2, 55.4, 54.6.

Anal. Calcd for $C_{14}H_{19}N_3O_5$ (309.32): C, 54.36; H, 6.19. Found: C, 54.12; H, 6.10.

Methyl (Methyl 2-azido-3-*O*-benzyl-2-deoxy-α-D-altropyranosid)uronate (24). The diol 23 (3.0 g, 9.7 mmol), KBr (300 mg) and TEMPO (60 mg) in sat. aq. NaHCO₃ (50 mL) was cooled to 0 °C and NaOCl solution (70 mL) was added dropwise to the vigorously stirred suspension. The mixture was allowed to warm up to rt and stirring was continued for 1 day when the solution become clear. The mixture was concentrated and co-concentrated with toluene (2 x 20 mL). The resulting white powder was suspended in *N*,*N*-dimethylformamide (15 mL), chilled and methyl iodide (6 mL) was added to the mixture and stirred for overnight. CH₂Cl₂ was added, the inorganic salts were removed by extractive work-up, the crude syrup was purified by chromatography (CH₂Cl₂/EtOAc, 8:2) to yield 24 (2.08 g, 64 %): $[\alpha]_D$ +67.2° (*c* 0.34); ¹H NMR δ 7.10 (m, 5H, aromatic), 4.98 (d, 1H, J_{1,2} = 3 Hz, H-1), 4.77 (t, 1H, J_{2,3} = 3 Hz, H-2), 4.47 (m, 2H, H-6, H-6'), 4.38 (dd, 1H, J_{3,4} = 3 Hz, J_{4,5} = 10 Hz, H-4), 3.99 (t, 1H, H-3), 3.39 (s, 3H, OCH₃); ¹³C NMR δ 98.2 (C-1), 76.5, 73.7, 72.6 (PhCH₂), 59.2, 55.4, 54.6.

Anal. Calcd for C₁₅H₁₉N₃O₆ (337.33): C, 53.41; H, 5.68. Found: C, 53.39; H, 5.66.

Methyl (Methyl 2-amino-3-O-benzyl-2-dcoxy- α -D-altropyranosid)uronate (25). To a solution of the azide 24 (2.0 g, 5.9 mmol) in MeOH (100 mL) were added pyridine (500 mL) and Pd-C (10%, 50 mg) and the mixture was vigorously stirred under H₂-atmosphere for 2 h. The catalyst was filtered off, the cake was washed with MeOH and the combined filtrates were concentrated. The crude syrup (1.76 g) was used for the next steps without purification.

Methyl (Methyl 3-*O*-benzyl-2-deoxy-2-phthalimido-α-D-altropyranosid) uronate (26). To a solution of the amine 25 (100 mg, 0.32 mmol) and triethylamine (100 μ L) in dry CH₂Cl₂ (10 mL) 2-methoxycarbonyl benzoyl chloride (0.38 mmol) was added at rt. The mixture was refluxed for overnight then concentrated and the resulting crude syrup was chromatographed (CH₂Cl₂/EtOAc, 95:5) to yield 26 (92 mg, 65%): ¹H NMR δ 7.73, 7.03 (2m, 2x5H, aromatic), 5.32 (d, 1H, J_{1,2} = 8.5 Hz, H-1), 4.77 (d, 1H, J_{4,5} = 2.5 Hz, H-5), 4.61, 4.36 (2d, 2H, PhCH₂), 4.56 (t, 1H, J_{3,4} = 3.0 Hz, H-4), 4.50 (dd, 1H, J_{2,3} = 11.0 Hz, H-2), 4.32 (dd, 1H, H-3), 3.86 (s, 3H, COOCH₃), 3.43 (OCH₃), 2.88 (bs, 1H, OH); ¹³C NMR δ 169.5 (COOCH₃), 167.9 (C=O), 97.3 (C-1), 74.9, 72.7, 66.4 (C-3, C-4, C-5), 71.7 (PhCH₂), 56.3 (COOCH₃), 52.5 (C-2), 51.4 (OCH₃).

Anal. Calcd for C₂₃H₂₃NO₈ (441.44): C, 62.58; H, 5.25. Found: C, 62.55; H, 5.24.

Methyl (Methyl 3-*O*-benzyl-2-deoxy-2-tetrachlorophthalimido-α-D-altropyranosid)uronate (27). To a solution of the amine 25 (100 mg, 0.32 mmol) in 2,2-dichloroethane (10 mL) tetrachlorophthalic anhydride (105 mg, 0.34 mmol) was added and the mixture was stirred for 15 min at rt. Diisopropylethylamine (500 µL) was added and the mixture was refluxed for overnight, then concentrated and purified by chromatography (CH₂Cl₂/EtOAc, 95:5) to yield pure 27 (144 mg, 78 %): ¹H NMR δ 7.0 (m, 5H, aromatic), 5.26 (d, 1H, $J_{1,2} = 8.5$ Hz, H-1), 4.78 (d, 1H, $J_{4,5} = 2.0$ Hz, H-5), 4.70, 4.27 (2d, 2H, PhCH₂), 4.58 (dd, 1H, $J_{3,4} = 3.0$ Hz, H-4), 4.45 (dd, 1H, $J_{2,3} = 11.0$ Hz, H-2), 4.24 (dd, 1H, H-3), 3.88 (s, 3H, COOCH₃), 3.42 (s, 3H, OCH₃), 2.78 (bs, 1H, OH); ¹³C NMR δ 169.3 (COOCH₃), 163.0 (C=O), 96.7 (C-1), 75.0, 73.4, 66. 7 (C-3, C-4, C-5), 72.4 (PhCH₂), 56.4 (COOCH₃), 52.7 (C-2), 52.2 (OCH₃).

Anal. Calcd for C₂₃H₁₉Cl₄NO₈ (579.22): C, 47.69; H, 3.31. Found: C, 47.68; H, 3.32.

302

Methyl (Methyl 3-*O*-benzyl-2-deoxy-2-trichloroacetamido-α-D-altropyranosid)uronate (28). To a solution of amine 25 (480 mg, 1.54 mmol) in dry CH₂Cl₂ (10 mL), were added triethylamine (500 µL) and trichloroacetyl chloride (190 µL, 1.7 mmol) at 0 °C, and the mixture was stirred for 1 h then concentrated and purified by chromatography (CH₂Cl₂/EtOAc, 98:2) to yield pure 28 (488 mg, 70 %) as a colourless syrup: ¹H NMR δ 7.35 (m, 5H, aromatic), 6.93 (d, 1H, $J_{2,NH}$ = 8.5 Hz, NH), 4.85, 4.60 (2d, 2H, PhCH₂), 4.82 (d, 1H, $J_{1,2}$ = 3.0 Hz, H-1), 4.56 (d, 1H, $J_{4,5}$ = 8.0 Hz, H-5), 4.33 (m, 1H, $J_{3,4}$ = 4.0 Hz, $J_{4,OH}$ = 8.0 Hz, H-4), 4.01 (bm, 1H, H-2), 3.92 (t, 1H, $J_{2,3}$ = 4. Hz, H-3), 3.81 (s, 3H, COOCH₃), 3.47 (s, 3H, OCH₃), 2.72 (bd, 1H, OH); ¹³C NMR δ 170.1 (COOCH₃), 161.8 (C=O), 99.3 (C-1), 74.3, 69.8, 65.9 (C-3, C-4, C-5), 71.9 (PhCH₂), 56.4 (COOCH₃), 52.6 (C-2), 50.9 (OCH₃).

Anal. Calcd for C₁₇H₂₀Cl₃NO₇ (456.71): C, 44.71; H, 4.41. Found: C, 44.72; H, 4.43.

Methyl [Methyl 3-*O*-benzyl-2-deoxy-2-(2,2,2-trichloroethoxycarbonylamino)α-D-altropyranosid]uronate (29). Prepared from 25 (525 mg, 1.7 mmol) as described above for the preparation of compound 28 to yield after chromatography (CH₂Cl₂/EtOAc, 98:2) 29 (430 mg, 52 %) as a colourless syrup: ¹H NMR δ 7.35 (m, 5H, aromatic), 5.65 (d, 1H, J_{2,NH} = 8.5 Hz, NH), 4.84, 4.56 (2d, 2H, PhCH₂), 4.73 (d, 1H, J_{1,2} = 2.0 Hz, H-1), 4.72 (s, 2H, Cl₃CCH₂), 4.50 (d, 1H, J_{4,5} = 8.5 Hz, H-5), 4.21 (m, 1H, H-4), 4.03 (bs, 1H, H-2), 3.84 (t, 1H, J_{2,3} = 4.0 Hz, J_{3,4} = 4.0 Hz, H-3), 3.79 (s, 3H, COOCH₃), 3.43 (s, 3H, OCH₃), 2.77 (bd, 1H, OH); ¹³C NMR δ 170.4 (COOCH₃), 153.9 (Cl₃CCH₂OCO), 100.1 (C-1), 95.2 (Cl₃CCH₂), 75.2, 69.4, 65.6 (C-3, C-4, C-5), 74.6 (Cl₃CCH₂), 71.6 (PhCH₂), 56.1 (COOCH₃), 52.5 (C-2), 50.2 (OCH₃).

Anal. Calcd for $C_{18}H_{22}Cl_3NO_8$ (486.73): C, 44.42; H, 4.56. Found: C, 44.42; H, 4.53.

General method for the glycosylation reactions with thioethyl glycosides

The solution of the acceptor (0.1 mmol) and the donor (0.11 mmol) in dry CH_2Cl_2 (1 mL) and 4 A molecular sieves (pellets) were stirred for 30 min at rt, then cooled to -40 °C. Solution of *N*-iodosuccinimide (0.13 mmol) and triflic acid (0.013 mmol) in dry CH_2Cl_2 (1 mL, containing 10% of dry tetrahydrofuran) was added dropwise to the solution. After 20 min triethylamine (100 µL) was added, the reaction mixture was

diluted with CH₂Cl₂ (20 mL), and after extractive work-up the crude syrup was purified by chromatography.

Methyl (3-O-Acetyl-4-azido-2,4,6-trideoxy-2-phthalimido- β -D-galactopyranosyl)-(1 \rightarrow 4)-3-O-benzyl-6-O-chloroacetyl-2-deoxy-2-phthalimido- α -D-altropyranoside (30). Glycosylation with thioglycoside: Prepared from ethyl 3-O-acetyl-4-azido-2,4,6trideoxy-2-phthalimido-1-thio- β -D-galactopyranoside⁸ (1) and 19 as described above. The crude mixture was purified by chromatography to yield pure 30 (30 mg, 33 %) as a colourless syrup.

Glycosylation with trichloroacetimidate: To a solution of the acceptor 19 (300 mg, 0.66 mmol) and the donor 7 (440 mg, 0.86 mmol) in dry CH₂Cl₂ (6 mL) was added molecular sieves (4 A, 200 mg) and the mixture was stirred for 30 min, then cooled to -50 °C and a solution of trimethylsilyl trifluoromethanesulfonate (50 µL in 500 µL of dry CH₂Cl₂) was injected. After 15 min triethylamine (200 µL) was added, the mixture was diluted with CH₂Cl₂ and after an extractive work-up chromatographed (CH₂Cl₂/EtOAc, 97:3) to yield pure **30** (400 mg, 73 %): [α]_D -93.1° (*c* 1.03); ¹H NMR δ 7.75 (m, 8H, aromatic), 7.11 (m, 5H, aromatic), 5.83 (dd, 1H, J_{2',3'} = 10.5 Hz, J_{3',4'} = 3.5 Hz, H-3'), 5.42 (d, 1H, J_{1',2'} = 8.0 Hz, H-1'), 4.89 (d, 1H, J_{1,2} = 6.0 Hz, H-1), 4.70 (dd, 1H, H-2'), 4.43 (dd, 1H, J_{2,3} = 8.0 Hz, H-2), 4.38 (dd, 1H, J_{3,4} = 3.5 Hz, J_{4,5} = 4.5 Hz, H-4), 4.29 (dd, 1H, H-3), 4.10 (s, 2H, ClCH₂), 3.92 (m, 1H, H-5'), 2.90 (s, 3H, OCH₃), 2.00 (s, 3H, CH₃CO), 1.33 (d, 3H, J_{CH3,5'} = 6 Hz, H-6'); ¹³C NMR δ 170.2 (ClCH₂CO), 167.7, 166.9 (C=O), 98.2 and 96.9 (C-1 and C-1'), 72.5, 71.8, 71.2 (PhCH₂), 70.69, 70.3, 69.4, 65.1 (C-6), 63.2, 54.8 (OCH₃), 52.5 and 51.1 (C-2 and C-2'), 40.7 (ClCH₂), 20.4 (CH₃CO), 17.3 (C-6).

Anal. Calcd for $C_{40}H_{38}ClN_5O_{13}$ (832.22): C, 57.73; H, 4.60. Found: C, 56.99; H, 4.53.

Methyl (3-O-Acetyl-4-azido-2,4,6-trideoxy-2-tetrachlorophthalimido-β-Dgalactopyranosyl)-(1→4)-3-O-benzyl-6-O-chloroacetyl-2-deoxy-2-tetrachlorophthalimido-α-D-altropyranoside (31). Prepared from 3 and 20 as described above and purified by chromatography (hexane/EtOAc, 75:25) to yield pure 31 (56 mg, 53 %) as a colourless syrup: $[\alpha]_D$ -53.8° (c 0.33); ¹H NMR δ 7.4 (m, 5H, aromatic), 5.77 (dd, 1H, $J_{2',3'} = 11.1, J_{3',4'} = 3.8$ Hz, H-3'), 5.45 (d, 1H, $J_{1',2'} = 8.3$ Hz, H-1'), 4.92 (d, 1H, $J_{1,2} = 6.9$ Hz, H-1), 4.72 (dd, 1H, H-2'), 4.08 and 4.1 (2s, 2H, CICH₂), 4.0 (dd, 1H, $J_{4',5'} = 1.0$ Hz, H-4'), 3.92 (bd, 1H, $J_{5',6'} = 6.3$ Hz, H-5'), 3.03 (s, 3H, OCH₃), 2.05 (s, 3H, CH₃CO), 1.39 (d, 3H, $J_{5',6'} = 6.3$ Hz, H-6'); ¹³C NMR δ 170.2 (CH₃CO), 97.9 (C-1), 94.8 (C-1'), 71.4 (PhCH₂), 71.1 (C-3'), 64.2 (C-6), 63.2 (C-4'), 55.7 (OCH₃), 52.7 (C-2), 51.5 (C-2'), 40.6 (CICH₂), 20.5 (CH₃CO), 17.4 (C-6').

Anal. Calcd for C₃₉H₃₀Cl₈N₅O₁₃ (1060.32): C, 44.18; H, 2.85. Found: C, 43.99; H, 2.87.

Methyl (3-*O*-Acetyl-4-azido-2,4,6-trideoxy-2-trichloroacetamido-β-D-galactopyranosyl)-(1→4)-3-*O*-benzyl-6-*O*-chloroacetyl-2-deoxy-2-trichloroacetamido-α-Daltropyranoside (32). Prepared from 4 and 21 as described above and purified by chromatography (CH₂Cl₂/EtOAc, 85:15) to yield pure 32 (21 mg, 24 %) as a colourless syrup: $[\alpha]_D$ –9.2° (*c* 0.1); ¹H NMR δ 7.3 (m, 5H, aromatic), 6.81 (d, 1H, J_{NH,2} = 7.9 Hz, NH), 6.61 (d, 1H, J_{NH,2} = 8.5 Hz, NH), 5.37 (dd, J_{2',3'} = 10.8, J_{3',4'} = 3.9 Hz, H-3'), 4.81 (d, 1H, J_{1',2'} = 8.2 Hz, H-1'), 4.59 (s, 1H, H-1), 4.38 (bs, 2H, PhC*H*₂), 4.07 (d, 2H, ClC*H*₂), 3.35 (s, 3H, OC*H*₃), 2.25 (s, 3H, C*H*₃CO), 1.19 (d, 3H, J_{5',6'} = 6.9 Hz, H-6'); ¹³C NMR δ 161.9 (Cl₃CCO), 128.3, 127.9 and 127.5 (aromatic), 100.6 (C-1'), 99.9 (C-1), 75.3, 75.4, 73.2, 72.9, 71.1, 69.6, 65.2, 64.2, 63.1, 56.1, 53.4, 52.3, 40.9 (ClC*H*₂), 20.4 (*C*H₃CO), 17.2 (C-6').

Anal. Calcd $C_{39}H_{30}Cl_7N_5O_{13}$ (1024.86): C, 45.71; H, 2.95. Found: C, 45.40; H, 3.00.

Methyl (3-*O*-Acetyl-4-azido-2,4,6-trideoxy-2-trichloroacetamido-β-D-galactopyranosyl)-(1→4)-(methyl 3-*O*-benzyl-2-deoxy-2-trichloroacetamido-α-D-altropyranosid)uronate (33). Prepared from 4 and 28 as described above and purified by chromatography (CH₂Cl₂/EtOAc, 85:15) to yield pure 33 (50 mg, 62 %) as a colourless syrup: $[\alpha]_D$ –34.6° (*c* 0.4); ¹H NMR δ 7.4 (m, 5H, aromatic), 6.87 (d, 1H, J_{2',NH} = 8.0 Hz, NH), 6.76 (d, 1H, J_{2,NH} = 7.6 Hz, NH), 5.54 (dd, 1H, J_{2',3'} = 11.1, J_{3',4'} = 3.8 Hz, H-3'), 4.99 (d, 1H, J_{1',2'} = 8.0 Hz, H-1'), 4.89 (d, 1H, J_{1,2} = 4.8 Hz, H-1), 4.60 (d, 1H, J_{4,5} = 5.9 Hz, H-5), 4.33 (dd, 1H, J_{3,4} = 3.1, H-4), 4.07 (dd, 1H, J_{2,3} = 7.3, H-3), 3.99 (m, 1H, H-2), 3.90 (m, 1H, H-2'), 3.86 (d, 1H, H-4'), 3.80 (d, 1H, J_{5',6'} = 6.3 Hz, H-5'), 3.46 (s, 3H, OCH₃), 2.11 (s, 3H, CH₃CO), 1.31 (d, 3H, J_{5',6'} = 6.3 Hz, H-6'); ¹³C NMR δ 170.2 (CH₃CO), 169.7 (COOCH₃), 161.9 and 161. 6 (Cl₃CCO), 99.1 (C-1), 98.7(C-1'), 93.3 (Cl₃C), 73.7 (C-3), 72.6 (PhCH₂), 72.0 (C-4), 71.1 (C-3'), 70.3 (C-5), 69.6 (C-5'), 63.2 (C-4'), 56.5 (OCH₃), 53.5 (C-2), 53.2 (C-2'), 52.8 (COOCH₃), 20.4 (CH₃CO), 17.3 (C-6').

Anal. Calcd for $C_{27}H_{31}Cl_6N_5O_{11}$ (814.29): C, 39.83; H, 3.84. Found: C, 39.9; H, 3.80.

Methyl (4-Azido-2-acetamido-2,4,6-trideoxy-β-D-galactopyranosyl)-(1→4)-(2acetamido-3-*O*-benzyl-2-deoxy-α-D-altropyranosid)uronic acid (34). To a solution of 33 (100 mg, 0.12 mmol) in MeOH(3 mL) was added solution of NaOH (1M, 1 mL) and the mixture was stirred for 3 days at rt. The mixture was then concentrated, the crude solid was dissolved in MeOH (3 mL) and Ac₂O (600 µL) was added at 0 °C. The stirring was continued for 1 h, then the mixture was concentrated and purified by chromatography (CH₂Cl₂/MeOH/H₂O, 7:3:0.5) to yield pure 34 (42 mg, 62 %) as a colourless glass: [α]_D – 22.7° (*c* 0.35, MeOH); ¹H NMR δ 7.3 (m, 5H, aromatic), 4.7 and 4.58 (2d, 2H, PhCH₂), 4.7 (2d, 1-1H, J_{1,2} = 5.0 Hz, J₁·2· = 8.5 Hz, H-1, H-1'), 4.61 (d, 1H, J_{4,5} = 6.0 Hz, H-5), 4.32 (dd, 1H, J_{3,4} = 3.0 Hz, H-4), 4.14 (dd, J_{2·3}· = 10.7 Hz, J_{3·4}· = 3.5 Hz, H-3'), 4.08 (dd, 1H, J_{3,4} = 3.0 Hz, H-2), 3.80 (dd, J_{2,3} = 7.0 Hz, H-3), 3.72 (m, 2H, H-4', H-5'), 3.63 (dd, 1H, H-2'), 3.40 (s, 3H, OCH₃), 1.97 and 1.92 (2s, 2x3H, CH₃CO), 1.30 (d, 3H, 6.4 Hz, H-6'); ¹³C NMR δ 174.3, 173.1, 171.4, 139.7, 129.3, 129.2, 101.4, 76.3, 74.3, 72.7, 72.2, 71.2, 70.8, 67.8, 56.3, 55.3, 52.2, 23.3, 22.7, 17.6.

Anal. Calcd for $C_{24}H_{33}O_{10}N_5$ (551.55): C, 52.26; H, 6.03. Found: C, 52.22; H, 6.00.

Methyl (2-Acetamido-4-amino-2,4,6-trideoxy-β-D-galactopyranosyl)-(1→4)-(2-acetamido-2-deoxy-α-D-altropyranosid)uronic acid (35). To a solution of 34 (40 mg, 0.07 mmol) in MeOH (3 mL) was added a solution of HCl (1M, 0.5 mL) and Pd(OH)₂ (10 mg), and the mixture was stirred vigorously under H₂ for 1 day, then was concentrated under vacuum and purified by chromatography (CH₂Cl₂/MeOH/H₂O, 5:5:0.5) to yield pure 35 (24 mg, 78 %) as a colourless glass: $[\alpha]_D$ +11.76° (*c* 0.12, H₂O); ¹H NMR δ 4.74 (d, 1H, J_{1,2} = 7.2 Hz, H-1'), 4.61 (d, 1H, J_{1,2} = 8.1 Hz, H-1), 3.99 (d, 1H, J_{2',3'} = 10.2, J_{3',4'} = 3.9 Hz, H-3'), 3.94 (dd, J_{2',3'} = 9.6 Hz, H-2'), 3.82 (dd, 1H, J_{2,3} = 10.2 Hz, H-2), 3.71 (dd, J_{3,4} = 2.95 Hz, H-3), 3.40 (dd, J_{4',5'} = 1.2 Hz, H-4'), 3.47 (s, 3H, OCH₃), 2.05 and 2.01 (2s, 2x3H, CH₃CONH), 1.31 (d, 3H, J_{5',6'} = 6.89 Hz, H-6'); ¹³C NMR δ 100.0, 99.84 (C-1, C-1'), 74.57, 70.55, 67.76, 67.58 and 67.31 (C-3, C-3', C-4, C-4' and C-5), 56.23, 53.22, 51.94 and 51.53 (C-5', C-2, C-2' and OCH₃), 22.24 and 22.02 (CH₃CONH), 15.66 (C-6').

Anal. Calcd for $C_{17}H_{29}O_{10}N_2$ (421.42): C, 48.45; H, 6.94. Found: C, 48.39; H, 6.88.

1,4,6-Tri-O-acetyl-2-azido-3-O-benzyl-2-deoxy-α,β-D-altropyranose (36). To a solution of 23 (1 g, 3.2 mmol) in Ac₂O (50 mL) was added H₂SO₄ (200 µL dissolved in 1 mL of Ac₂O) at 0 °C and the stirring was continued for 3h. The mixture was poured on ice cold solution of NaHCO₃, extracted with CH₂Cl₂, the organic layer was washed with NaHCO₃ solution until neutral, dried and concentrated. The crude syrup was passed through a short column of silica (CH₂Cl₂/EtOAc, 95:5) to yield pure 36 (1.2 g, 89 %) as a colourless syrup: $[\alpha]_D$ -74.7° (*c* 0.54); ¹H NMR 7.3 (m, 5H, aromatic), 6.15 (d, J_{1,2} = 2.5 Hz, H-1α), 5.80 (d, J_{1,2} = 4.3 Hz, H-1β), 5.15 (dd, J_{3,4} = 3.1, J_{4,5} = 6.2 Hz, H-4α), 5.07 (dd, J_{3,4} = 3.1, J_{4,5} = 6.8 Hz, H-4β), 4.56 (m, PhCH₂), 4.28 (m, H-5), 2.03, 2.02 and 1.98 (3s, CH₃CO); ¹³C NMR 91.9 (C-1β), 91.4 (C-1α), 74.3, 73.5, 73.2, 72.7, 72.5, 70.2, 65.9 (PhCH₂), 62.6 and 62.3 (C-6α,β), 59.8 and 59.5 (C-2α,β), 20.9 and 20.8 (CH₃CO).

Anal. Calcd for C₁₉H₂₃N₃O₈ (421.41): C, 54.15; H, 5.50. Found: C, 54.12; H, 5.54.

Ethyl 4,6-Di-O-acetyl-2-azido-3-O-benzyl-2-deoxy-1-thio-α,β-D-altropyranoside (37). To an ice cold solution of 36 (2 g, 4.8 mmol) in dry CH₂Cl₂ (20 mL) were added EtSH (5 mmol) and SnCl₄ (4.8 mmol) and the mixture was stirred at 0 °C for 1h. The mixture was diluted with CH₂Cl₂, washed until neutral with NaHCO₃ solution, dried, concentrated and chromatographed (hexane/EtOAc, 8:2) to yield 37 (1.5 g, 75 % overall) as α and β mixture: 37β [α]_D + 17.20° (*c* 0.33) and 37α [α]_D +94.87° (*c* 0.67); ¹³C NMR 170.5 and 169.7 (C=O), 82.6 (C-1), 74.3 (C-5), 72.6 and 67.5 (C-3,4), 66.2 (C-6), 62.3 (PhCH₂), 61.6 (C-2), 26.6 (SCH₂CH₃), 20.7 and 20.6 (*C*H₃CO), 14.9 (SCH₂CH₃).

Anal. Calcd for C₁₉H₂₅N₃SO₆ (423.48): C, 53.89; H, 5.95. Found: C, 53.9; H, 5.86.

Ethyl 4,6-Di-O-acetyl-3-O-benzyl-2-deoxy-1-thio-2-trichloroacetamido- α,β -Daltropyranoside (38). A solution of 36 (450 mg, 1.06 mmol) in EtOAc (30 mL) containing PtO₂ catalyst (50 mg) was stirred vigorously under H₂ for 2h. The mixture was cooled to 0 °C, Et₃N (443 µL, 3.18 mmol) and trichloroacetyl chloride (130 µL, 1.2 mmol) were added and the stirring was continued for an additional 1 h. The catalyst was filtered off, the filtrate was extracted with water, dried, concentrated and chromatographed (hexane/EtOAc, 8:2) to yield pure 38 (350 mg, 62 %) as a colourless oil: $[\alpha]_D$ +87.46° (*c* 0.44); ¹H NMR 7.3 (m, 5H, aromatic), 6.95 (d, 1H, J_{2,NH} = 7.9 Hz, NH), 5.12 (bs, 1H, H-1), 4.87 (dd, 1H, J_{4,5} = 9.8, J_{3,4} = 3.3 Hz, H-4), 4.73 and 4.47 (2d, 2H, PhCH₂), 4.72 (bm, 1H, H-2), 4.34 (m, 1H, J_{5,6} = 2.6, J_{5,6} = 4.6 Hz, H-5), 4.29 (dd, 1H, J_{6,6} = 12.5 Hz, H-6), 4.03 (dd, 1H, H-6'), 3.96 (t, 1H, J_{2,3} = 3.6 Hz, H-3), 2.58 (m, 2H, SCH₂CH₃), 2.0 and 1.88 (2s, 2x3H, CH₃CO), 1.24 (t, 3H, SCH₂CH₃). ¹³C NMR 170.5 and 169.6 (CH₃CO), 161.1 (Cl₃CCONH), 83.2 (C-1), 72.5 (C-5), 72.2 and 66.1 (C-3,4), 65.9 (C-6), 62.4 (PhCH₂), 53.2 (C-2), 27.4 (SCH₂CH₃), 20.63 (CH₃CO), 15.1 (SCH₂CH₃).

Anal. Calcd for $C_{21}H_{26}NCl_3SO_7$ (542.86): C, 46.46; H, 4.83. Found: C, 46.38; H, 4.86.

Methyl (4,6-Di-O-acetyl-3-O-benzyl-2-deoxy-2-trichloroacetamido-α-Daltropyranosyl)- $(1 \rightarrow 3)$ -4-azido-2,4,6-trideoxy-2-trichloroacetamido- β -D-galactopyranoside (39). A solution of the glycosyl donor 38 (170 mg, 0.32 mmol) and methyl 4azido-2,4,6-trideoxy-2-trichloroacetamido-β-D-galactopyranoside (90 mg, 0.26 mmol) in dry acetonitrile (1.5 mL) containing freshly fused molecular sieves (4 A) was stirred for 20 min at -30 °C, then a mixture of NIS (110 mg, 0.38 mmol) and TfOH (5 µL) in dry acetonitrile (600 µL) was added dropwise. After 15 min trimethylamine (200 µL) was added, then the mixture was diluted with CH₂Cl₂, extracted with Na₂S₂O₃ solution, dried, concentrated and chromatographed (CH2Cl2/acetone, 9:1) to yield pure 39 (180 mg, 84 %) as a colourless syrup: $[\alpha]_D$ -82.7° (c 0.5); ¹H NMR 7.25 (m, 5H, aromatic), 6.90 and 6.75 (2d, 1-1H, $J_{NH,2} = J_{NH,2'} = 7.2$ Hz, NH), 5.23 (d, 1H, $J_{1',2'} = 4.0$ Hz, H-1'), 5.07 (dd, 1H, $J_{4',5'} = 6.56$, $J_{3',4'} = 3.6$ Hz, H-4'), 4.75 (d, 1H, $J_{1,2} = 8.2$ Hz, H-1), 3.78 (dd, 1H, $J_{4,5} =$ 1, $J_{3,4} = 3.6$ Hz, H-4), 3.62 (m, 1H, H-5), 3.49 (m, 1H, $J_{2,3} = 10.8$ Hz, H-2), 3.41 (s, 3H, OCH₃), 2.03 and 1.96 (2s, 2x3H, CH₃CO), 1.29 (d, 3H, J_{5,6} = 6.2 Hz, H-6); ¹³C NMR 170.6 and 169.8 (CH₃CO), 161.9 (Cl₃CCONH), 99.7 (C-1), 95.02 (C-1'), 74.3 (C-3), 72.2, 71.8, 69.1 (C-5',3',4'), 66.01 (C-4), 62.1 (C-6'), 61.7 (PhCH₂), 56.9 and 55.0 (C-2,2'), 53.1 (OCH₃), 20.7 (CH₃CO), 17.5 (C-6).

Anal. Calcd for $C_{28}H_{33}O_{11}N_5Cl_6$ (828.31): C, 40.60; H, 4.02. Found: C, 40.51; H, 4.00.

Methyl (3-O-Benzyl-2-deoxy-2-trichloroacetamido-α-D-altropyranosyl)-(1 \rightarrow 3)-4-azido-2,4,6-trideoxy-2-trichloroacetamido-β-D-galactopyranoside (40). To a stirred, ice cold solution of 39 (100 mg, 0.12 mmol) in MeOH (10 mL) was added acetyl chloride (100 μ L) and the stirring was continued at rt for 1 day. The solution was concentrated and chromatographed (CH₂Cl₂/acetone, 8:2) to yield pure 40 (60 mg, 69 %) as a colourless syrup: [α]_D +63.56° (*c* 0.3); ¹H NMR 7.30 (m, 5H, aromatic), 5.0 (d, 1H, J_{1',2'} = 1.3 Hz, H-1'), 4.61 (d, 1H, J_{1,2} = 8.2 Hz, H-1), 3.40 (s, 3H, OCH₃), 1.40 (d, 1H, H-6); ¹³C 162.3 (NHCO), 100.2 (C-1), 93.9 (C-1'), 73.9, 72.6, 71.6, 69.5, 68.8, 62.9 (C-4), 60.7 and 60.6 (C-6' and CH₂Ph), 56.7 and 53.9 (C-2,2'), 50.3 (OMe), 17.2 (CH₃).

Anal. Calcd for $C_{24}H_{24}O_8N_5Cl_6$ (723.20): C, 39.86; H, 3.34. Found: C, 39.79; H, 3.34.

Methyl [(3-*O*-Benzyl-2-deoxy-2-trichloroacetamido-α-D-altropyranosyl) uronic acid)]-(1 \rightarrow 3)-4-azido-2,4,6-trideoxy-2-trichloroacetamido-β-D-galactopyranoside (41). To a solution of diol 40 (80 mg, 0.1 mmol) in CH₂Cl₂ (2 mL) were added TEMPO (5 mg), KBr (3 mg), tetraethylammonium chloride (3 mg) and sat. aq. NaHCO₃ (5 mL) and then cooled to 0 °C. A solution of NaOCI (5 mL) was added dropwise to the vigorously stirred solution at 0 °C and the stirring was continued for 30 min. The mixture was acidified by addition of 1M HCl solution, then extracted with CH₂Cl₂ (3 x 10 mL), the combined organic phases were washed until neutral with water, dried and concentrated. Chromatography (CH₂Cl₂/acetone, 7:3) yielded pure 41 (52 mg, 70 %): [α]_D+19.89° (*c* 0.15); ¹H NMR 7.3 (m, 5H, aromatic), 5.3 (d, 1H, 7.4 Hz, H-1'), 4.46 (d, 1H, J_{1,2} = 8.0 Hz, H-1), 4.34 (dd, 1H, J_{3,4} = 3.7, J_{2,3} = 11.0 Hz, H-3), 3.45 (s, 3H, OCH₃), 1.33 (d, 3H, J_{5,6} = 6.1 Hz, H-6); ¹³C NMR 103.6 and 97.5 (C-1, C-1'), 78.3, 77.3, 76.4, 72.3, 71.2, 67.5, 63.9, 57.3 and 54.5 (C-2,2'), 54.1 (OCH₃, 17.7 (C-6).

Anal. Calcd for $C_{24}H_{22}O_9N_5Cl_6$ (737.18): C, 39.10; H, 3.01. Found: C, 39.01; H, 3.06.

Methyl [(2-Acetamido-2-deoxy-α-D-altropyranosyl)uronic acid]-(1 \rightarrow 3)-2acetamido-4-amino-2,4,6-trideoxy-β-D-galactopyranoside (43). Compound 41 (45 mg, 0.06 mmol) was deprotected as described earlier (for compounds 34, 35) to yield after chromatography (CH₂Cl₂/MeOH/H₂O, 6:4:0.3) pure 43 (11 mg, 40 %) as a colourless glass: [α]_D – 10.85° (*c* 0.11, H₂O); ¹H NMR (D₂O) 4.91 (d, 1H, J₁,₂ = 6.5 Hz, H-1'), 4.46 (d, 1H, J_{1,2} = 8.5 Hz, H-1), 4.37 (d, 1H, J₄,₅ = 4.0 Hz, H-5'), 4.27 (t, 1H, J₄,₅ = 4.0 Hz, H-4'), 4.04 (dd, 1H, J₁,₂ = 6.5 Hz, J₂,₃ = 9.0 Hz, H-2'), 3.99 (bd,1H, J_{5,6} = 6.0 Hz, H-5), 3.92 (dd, 1H, J_{1,2} = 8.5 Hz, J_{2,3} = 11 Hz H-2), 3.77 (dd, 1H, J₂,₃ = 9.0 Hz, J₃,₄ = 3.0 Hz, H-3'), 3.55 (OC*H*₃), 2.07 and 2.09 (2s, 2x3H, C*H*₃CONH), 1.35 (d, 3H, J_{5,6} = 6.0 Hz, H-6); ¹³C NMR 105.0 (C-1), 101.2 (C-1'), 78.3 (C-5'), 71.6 (C-4'), 71.3 (C-5'), 71.0 (C-3'), 60.0 (OCH₃), 54.4 (C-2'), 52.6 (C-2), 25.0 (2xCH₃CONH), 18.2 (C-6).

ACKNOWLEDGEMENT

This work was supported by an International Research Scholar's award from the Howard Hughes Medical Institute. The Hungarian Scientific Research Fund OTKA F19482 and the Mizutani Foundation also supported these investigations. Generous support from Bolyai Postdoctoral Scholarship to I. Bajza is also acknowledged.

REFERENCES

- 1. M.W Binns, S. Vaugham and K.N. Timmis, Z. Bacteriol. Microbiol. Hyg. Abt. 1. Orig. B., 181, 197 (1985).
- 2. J.B. Robbins, C. Chu and R. Schneerson, Clin. Infect. Dis., 15, 346 (1992).
- 3. J.B. Robbins, R. Schneerson, S. Szu and V. Pozsgay, in *Vaccinia, Vaccination and Vaccinology: Tenner, Pasteur and their Successors*, S. Plotkin, B. Fantini (Eds.), Elsevier, Paris, 1996, p 135.
- 4. J.B. Robbins, R. Schneerson, S. Szu and V. Pozsgay, *Pure Appl. Chem.*, in press (1999).
- 5. T. Kontrohr, Carbohydr. Res., 58, 498 (1977).
- 6. L. Kenne, B. Lindberg, K. Petersson, E. Katzenellenbogen and E. Romanowska, *Carbohydr. Res.*, 78, 119 (1980).
- 7. Gy. Batta, A. Lipták, R. Schneerson and V. Pozsgay, Carbohydr. Res., 305, 93 (1997).
- 8. A. Medgyes, E. Farkas, A. Lipták and V. Pozsgay, Tetrahedron, 53, 4159 (1997).
- O. Kanie, S.C. Crawley, M.M. Palcic and O. Hindsgaul, Carbohydr. Res., 243, 139 (1993).
- 10. J.S. Debenham, R. Rodebaugh and B. Fraser-Reid, Liebigs Ann./Recueil, 791 (1997).
- 11. G. Blatter, J.-M. Beau and J.-M. Jacquinet, Carbohydr. Res., 260, 189 (1994).
- W. Dullenkopf, J.C. Castro-Palomino, L. Manzoni and R.R. Schmidt, *Carbohydr. Res.*, 296, 135 (1996).
- 13. P. Fügedi, P.J. Garegg, H. Lönn and T. Norberg, Glycoconjugate J., 4, 97 (1987).
- For review on nitroxyl radical mediated oxidations see: A.E.J. de Noy, A.C. Besemer and H. van Bekkum, Synthesis, 1153 (1996).
- 15. R.R. Schmidt, Pure Appl. Chem., 61, 1257 (1989). R.R. Schmidt and W. Kinzy, Advances in Carbohydr. Chem. Biochem., 50, 21 (1994).
- G.H. Veeneman, S.H. van Leeuwen and J.H. van Boom, *Tetrahedron Lett.*, 31, 1331 (1990).
 P. Konradsson, U.E. Udodong and B. Fraser-Reid, *Tetrahedron Lett.*, 31, 4313 (1990).
- 17. I. Farkas, M. Menyhárt, R. Bognár and H. Gross, Chem. Ber., 98, 1419 (1965).

- 18. N.J. Davies and S.L. Flitsch, Tetrahedron Lett., 34, 1181 (1993).
- 19. P.L. Anelli, S. Banfi, F. Montanari and S. Quici, J. Org. Chem., 54, 2970 (1989).
- 20. N.M. Spijker and C.A.A. van Boeckel, Angew. Chem. Int. Ed., 30, 180 (1991).